Evidence map›Paper›PMID 26759056›Full record

Trial reportBMC infectious diseases2016

HPV Vaccine utilization, Alberta 2008/09-2013/14 School year.

Xianfang C Liu, Christopher A Bell, Kimberley A Simmonds, Margaret L Russell, Lawrence W Svenson

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Distribution of HPV genotypes among women with abnormal cytology results in Alberta, Canada.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2021
    Article
  3. Review
  4. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Xianfang C LiuDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada. xcliu@ucalgary.ca.
Christopher A BellEpidemiology and Surveillance Team, Alberta Ministry of Health, 23rd fl Telus Plaza NT, 10025 Jasper Avenue, Edmonton, AB, T5J 1S6, Canada. chris.bell@gov.ab.ca.
Kimberley A SimmondsEpidemiology and Surveillance Team, Alberta Ministry of Health, 23rd fl Telus Plaza NT, 10025 Jasper Avenue, Edmonton, AB, T5J 1S6, Canada. kimberley.simmonds@gov.ab.ca.
Margaret L RussellDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada. mlrussel@ucalgary.ca.
Lawrence W SvensonDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada. larry.svenson@gov.ab.ca.
Ministry of Health · CAUniversity of Calgary · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Canada both bivalent (bHPV) vaccine and quadrivalent HPV vaccine (qHPV) are authorized for use. In Alberta, while both vaccines are available for private purchase, only qHPV is publicly funded for school girls in grades 5 and 9 as of 2013. We describe HPV vaccine uptake in Alberta, by school year, from the start of the publicly funded program in the Fall of 2008 through to August 31(st) 2014 and estimate the cumulative proportion of the female population who were vaccinated by the end of the 2013/14 school year.

methodsWe used data from the Alberta Ministry of Health Immunization and Adverse Reaction to Immunization repository (publicly funded vaccine), the population-based Pharmaceutical Information Network information systems (privately purchased vaccine) for the period September 1, 2008 to August 31, 2014 and demographic data from the Alberta Health Care Insurance Plan Registry. We estimate vaccine uptake rates and explore them by attributes of person, time, place, vaccine funding, and number of doses received. We estimated the cumulative proportions of the female population (by age group and number of doses received) who had received HPV vaccine by the end of the 2013/14 school year.

resultsOf the 169,259 unique individuals who received one or more doses of HPV vaccine over the period, 98.3% were females, and 83.8% received publicly funded vaccines. Vaccine uptake increased over the period. The cumulative proportion of females aged 9-26 years as of 2013/14 who had received two or more doses of vaccine was 34.3%; for those aged 10-11 years 59.6% and for those aged 14-15 years, 76.0%. For those aged 9-26 years, 31.3% had received three doses of vaccine.

conclusionHPV vaccine uptake rates have increased in Alberta over the study period, most prominently among the age groups targeted by the publicly funded school-girl vaccine program.

Indexed as

AdolescentAdultAlbertaChildFemaleHumansImmunization ProgramsMalePapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesProgram EvaluationSchoolsVaccinationYoung AdultPapillomavirus Vaccines

Identifiers

PMID26759056
PMCPMC4711033
OpenAlexW2239266188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.